NCT02411526View on ClinicalTrials.gov

Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

ZX003 (Risperidone-SABER®)

ZX003 administered as a SC injection

DRUG

Risperdal Consta

Risperdal Consta administered as a IM injection

DRUG

Oral Risperidone

Oral Risperidone given to ensure adequate therapeutic plasma concentrations from Risperdal Consta

Trial Locations (1)

90806

Collaborative Neuroscience Network, Long Beach

All Listed Sponsors
lead

Zogenix, Inc.

INDUSTRY

NCT02411526 - Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia | Biotech Hunter | Biotech Hunter